by TractManager | Nov 23, 2016 | Emerging Technology Report
A transcatheter, miniaturized, single-chamber, leadless cardiac pacemaker proposed to reduce risk for lead-related complications associated with conventional pacemakers.If you have a Hayes login, click here to view the full report on the Knowledge Center.
by TractManager | Nov 22, 2016 | Molecular Test Assessment
The PancraGEN test is a molecular-based cancer diagnostic test that combines molecular genetic testing with current nongenetic diagnostic methods. It is offered, in conjunction with first-line testing or as a second-line test when...
by TractManager | Nov 22, 2016 | Molecular Test Assessment
Heart transplantation is a widely accepted therapy for the treatment of end-stage cardiac disease. Approximately 20,000 people in the United States now live with a transplanted heart. Survival is nearly 90% at 1 year, 74.0% at 5 years, and the median survival is more...
by TractManager | Nov 17, 2016 | Molecular Test Assessment
An estimated 180,890 new cases of prostate cancer will be diagnosed in 2016, which accounts for 10.7% of all new cancer cases in the United States. Prostate cancer is the second leading cause of cancer death in the United States, with approximately 12.9% of men being...
by TractManager | Nov 10, 2016 | Health Technology Assessment
Purpose of Technology: Extracorporeal shock wave therapy (ESWT) is a noninvasive treatment for chronic plantar fasciitis that involves delivery of shock waves to the painful region of the heel with the goal of reducing pain, increasing function, and promoting healing...
Recent Comments